Such a strategy is also applied by others in clinical trials in patients with solid tumors using c-MET as a CAR-target antigen on breast cancer and melanoma [65], (NCT01837602; NCT03060356) and mesothelin as a CAR-target antigen on mesothelioma, pancreatic cancer, and ovarian cancer [66,67,68], (NCT03608618; NCT01897415; NCT01355965), or even with non-solid tumors using CD19 and CD123 as target antigen [69], (NCT02277522; NCT02624258; NCT02623582). This evidence concerns the gene MSLN and ovarian carcinoma.